Year-end Sale % OFF 
Abstract
Background: MicroRNAs (miRNAs) are key gene regulators that are involved in many biÂological and also pathological processes, including breast cancer. Breast cancer is the most common form of malignancies in women and requires new therapies and biomarkers. Different signaling pathways, such as Phosphoinositide 3-kinase (PI3K) signaling pathway are involved in breast cancer and can be new candidates for targeted therapies based on miRNAs. The aim of this study was to predict miRNAs targeting Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and serine/threonine kinase 1 (AKT1) genes of PI3K cascade bioinformatically and to analyze their expression in breast cancer. Materials and Methods: Bioinformatic software and tools were used to predict miRNAs targeting PIK3CA and AKT1 genes. MCF-7 and MCF-10A cell lines were cultured as breast cancer and control cells respecÂtively. RNA extraction, cDNA synthesis, and quantitative real-time PCR were performed. REST 2009® was utilized to analyze the expression of miRNAs and their target genes. Results: The results of our bioinformatic predictions indicated that miR-576-5p, miR-501-3p, and miR-3143 can be the first candidate miRNAs targeting PI3K signaling pathway. Data analyses demonÂstrated that PIK3CA and AKT1 genes were up-regulated while all bioinformatically predicted miRNAs were down-regulated in MCF-7 cell line compared to the normal cells. Conclusion: The results of our study demonstrated that PIK3CA and AKT1 can be targeted by miR-576-5p and miR-501-3p respectively. Furthermore, miR-3143 can target both mRNAs. Since these miRNAs target oncogenes, they can be proposed for new complementary targeted therapies in breast cancer patients. [GMJ.2017;6(4):338-45] DOI: 10.22086/gmj.v6i4.925
Highlights
MicroRNAs are a class of non-coding RNAs with a length of ~22 nucleotides
After performing Real-time Polymerase Chain Reaction (PCR) and applying ∆∆CT method in REST® 2009 software for data analysis, the final results demonstrated that the expression level of all three miRNAs significantly decreased in MCF-7 cell line compared to the normal breast cell line
The results showed that the expression level of both PIK3CA and AKT1 genes significantly increased by 8.2 and 2 folds respectively in MCF-7 cell line compared to the normal cells (Figure-2)
Summary
MicroRNAs (miRNAs) are a class of non-coding RNAs with a length of ~22 nucleotides. These endogenous molecules bind to the 3′-untranslated region (3′-UTR) of their target mRNAs and cause gene silencing at post-transcriptional level [1,2,3]. Reducing the activity of this pathway by miRNAs targeting key genes of this cascade can be considered an interesting clinical strategy for breast cancer treatment [12,13,14,15,16,17]. MiRNAs which target PIK3CA and AKT1 genes of PI3K pathway were predicted by means of bioinformatics software and the expression level of these novel predicted miRNAs were evaluated. Breast cancer is the most common form of malignancies in women and requires new therapies and biomarkers Different signaling pathways, such as Phosphoinositide 3-kinase (PI3K) signaling pathway are involved in breast cancer and can be new candidates for targeted therapies based on miRNAs. The aim of this study was to predict miRNAs targeting Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and serine/threonine kinase 1 (AKT1) genes of PI3K cascade bioinformatically and to analyze their expression in breast cancer.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
